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cohort of 1553 patients was identiﬁed (females = 58%). The
mean age was 43 years (range: <1–94 years). A total of 2459
encounters were identiﬁed during one year (mean encounters per
patient = 1.6, range: 1–18) and 12% of patients used more than
one location of care. Hospitalizations were 78%, ED visits were
18%, and OU stays were 4% of all encounters. On average, an
inpatient stay was 5.6 days at a cost of $8354. Mean ED visit
was ﬁve hours (average cost of $838). Mean OU stay was 28
hours (average cost of $2457). Cumulative cost for all inpatient,
ED and OU encounters for these patients for one year was
roughly $17.3 million and this is a conservative estimate of man-
agement costs, as it does not include physician, post-acute or
usual outpatient care costs. CONCLUSIONS: These results
show that managing this disorder requires use of resource inten-
sive settings at a substantial cost and provide key information
for health economic analyses of Crohn’s disease.
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OBJECTIVES: To evaluate OTC Prilosec Step Care programs on
the utilization and costs of Proton Pump Inhibitors (PPI) in a
large pharmacy beneﬁt management setting. METHODS: Using
pre-post with control group study design, prescription records
from January 1, 2003 to October 31, 2004 were obtained from
pharmacy claims database in a large pharmacy beneﬁt manage-
ment organization. Clients were assigned to one of the four
cohorts—formulary changes and step care, step care only, for-
mulary change only, no formulary change and no step care
(serves as the control group). The number of prescriptions dis-
pensed and the total costs per member per month (PMPM) were
analyzed and compared among the groups. RESULTS: From the
pre to post period, in the cohort with formulary change and step
care, the average number of prescriptions per month decreased
by 50.2% and the average PMPM costs decreased by 55.8%
(from $3.44 to $1.52). In the step care only cohort, the number
of prescriptions decreased by 34% and the average PMPM costs
decreased by 25.4% (from $4.2 to $3.13). In the formulary
change only cohort, the number of prescriptions decreased by
12% and the average PMPM costs decreased by 22.7% (from
$3.38 to $2.61). In the control group, the number of prescrip-
tions decreased by 18.9%, while the average PMPM costs
increased by 3.3% (from $4.06 to $4.19). OTC Prilosec Step
Care programs resulted in PMPM and total annualized cost
savings, $2.03 and $4,727,058 for the cohort with formulary
change and step care, $1.21 and $757,915 for the cohort with
step care only, $0.88 and $1,230,662 for the cohort with for-
mulary change only. CONCLUSIONS: OTC Prilosec Step Care
programs were found to be very effective in controlling the uti-
lization and expenditures on PPIs.
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OBJECTIVES: The differential effects of non speciﬁc non-
steroidal anti-inﬂammatory agents (NSAIDs) compared with
cyclooxygenase-2 inhibitors (COX-2) on gastrointestinal (GI)
side effects have led to the preference of COX-2s over NSAIDs.
The purpose of this study is to evaluate the gastrointestinal risk
of NSAIDs compared with COX-2 inhibitors in a Medicaid
managed care population. METHODS: Medical and prescrip-
tion claims were analyzed for all Medicaid enrollees, 18 and
older, who received a COX-2 or other prescription NSAID
between June, 2000 and June, 2002 and who did not use these
drugs for at least six months prior. These Medicaid plans have
prior authorization conditions. A logistic model was developed
of the propensity for treatment with NSAIDs and stratiﬁed
patients by quintiles of their propensity score. The propensity
that a given patient will be assigned an NSAID or a COX-2 was
then assessed. Patients might have similar propensity scores but
in fact receive different treatments, hence grouping people with
similar scores can provide a basis to observe the treatment effect
in patients with similar risk proﬁles. The model adjusted for
demographics, indications for NSAIDs and GI risks. We com-
pared GI event (ICD-9 codes 531–534, 578) rates between
NSAID and COX-2 users. RESULTS: Out of a total of 64,053
patients (including 574 COX-2 users), 73% were female, 43%
Caucasian, and 29% older than 50. In the propensity adjusted
model, there was no signiﬁcantly higher rate of GI events in
NSAID users as compared to COX-2 users (OR = 0.738, 95%
CI 0.486, 1.121). CONCLUSIONS: We did not ﬁnd a signiﬁcant
difference in the GI event rates among patients in this Medicaid
population who are started on NSAIDs vs. COX-2 inhibitors. In
their decisions, managed care plans might consider possible
selection bias, due to prior authorization, and not captured by
the propensity adjustment.
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OBJECTIVE: In 1989, Germany was ﬁrst country to introduce
reference based pricing (RBP) to cap drug costs. Initially RBP
was only applicable to identical ingredients. In 1992 and 1993,
RBP was extended to chemically similar drugs of the same indi-
cation. In 2004, the German government seeks to extend RBP to
patent-protected drugs. With that measure the government
expects major cost-savings. Taking PPI (protonpumpinhibitors)
in the treatment of GERD (gastroesophageal reﬂux disease) as
an example we demonstrate that the expected savings are not
going to be realized. METHODS: A markov model was con-
structed to evaluate the effect of RBP on the clinical outcomes
and costs in the maintenance therapy of GERD. It is assumed
that payments by the patients in case of a drug price above the
reference price have an effect of on the continuation of the
therapy. Refusal of payments by the patient can lead to a change
or discontinuation of the initially chosen therapy. RESULTS:
Due to changes in treatment patterns and the more frequent use
of less effective PPI, only 18% of the expected savings are real-
ized. Hence the likelihood of remission per year decrease from
79% to 73% and 6% more hospital admissions are to be
expected. CONCLUSIONS: Only a fraction of the expected
costs are going to be realized, while the overall effectiveness
decreases substantially. The inclusion of patented drugs in refer-
ence price schemes should be assessed individually.
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OBJECTIVE: Many conditions have strong diurnal components
which may inﬂuence work productivity. We evaluate the rela-
tionship between sleep impairment and productivity loss using
symptomatic daytime vs. nighttime gastro-esophageal reﬂux
disease (GERD) as an example. METHODS: An Internet survey
of employed US adults measured GERD symptom frequency and
severity (prior 12 months and prior seven days). GERD status
was assessed with the validated GERD-SMQ. General health-
related and GERD-speciﬁc productivity losses were evaluated
using the WPAI questionnaire. Nighttime sleep impairment (SI)
was assessed by a panel of six questions concerning sleep prob-
lems. Our conceptual framework modeled the impact of night-
time symptoms as causing SI which, in turn, inﬂuences daytime
work productivity. Thus, two-equations: 1) SI as a function of
GERD status (and covariates); and 2) WPAI as a function of SI
(and covariates), were simultaneously estimated using three-
stage least squares (3SLS) regression. Results were compared to
those of an alternative instrumental variables speciﬁcation.
RESULTS: Of 65,001 individuals invited to participate, 13,231
(21.4%) responded. A total of 1002 were symptomatic GERD
cases (476 nighttime vs. 526 daytime) which were included in
the analysis. 3SLS showed nighttime vs. daytime GERD was
associated with a signiﬁcant increase in SI (D = 33.6%, p <
0.001). Respondents with severe or very severe GERD also expe-
rienced greater SI (D = 39.1%, p < 0.005). SI was shown to have
a large impact on work productivity (elasticity = 5.4%, p <
0.001). c2 values were 384 (p < 0.0001) and 84.5 (p < 0.0001)
for the ﬁrst and second equations. 3SLS results were consistent
with the IV speciﬁcation. CONCLUSIONS: Nighttime GERD
symptoms signiﬁcantly impair sleep which results in reductions
in daytime work productivity. The impact of the distinct diurnal
nature of chronic conditions is little understood. This framework
may prove useful in evaluating similar chronic health conditions
(eg, asthma) and related adverse events due to medication use.
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OBJECTIVES: To determine whether the Medication Possession
Ratio (MPR) alone or in combination with Breakthrough Events
(BEs), was more likely to differentiate between patients.
METHODS: Medical and prescription claims for MCO enrollees
diagnosed with or receiving therapy for Acid Related Diseases
(ARD) between July 1, 2001 and June 30, 2003 in the Phar-
metrics database were retrieved. Selected for study were persons
over 18 with an ARD diagnosis and a minimum 30 days supply
during the time period for study inclusion. The study classiﬁed
ARD patients by their MPR alone and in combination with spec-
iﬁed BEs into ﬁve cohorts and examined how each classiﬁcation
method was able to correctly differentiate persons based on their
economic data, utilization data, ARD-speciﬁc comorbidities, and
other comorbidities through paired comparison tests. Pairwise
group comparisons were made between cohorts using Bonfer-
roni’s (Dunn’s) method for multiple comparisons of continuous
variables and chi-squared paired comparison tests for discrete
variables. Differences were considered to be statistically signiﬁ-
cant if p <= 0.05. RESULTS: The study identiﬁed a population
of 79,454 persons with 700,846 claims for PPI prescriptions
during the two-year time frame. Overall, the analysis plan iden-
tiﬁed 760 possible matched pair comparisons and 43 compar-
isons between the top two cohorts. The MPR alone method iden-
tiﬁed 523 (68.8%) and the MPR combination method identiﬁed
464 (61.1%) signiﬁcant pairwise comparisons. In comparing the
top two cohorts, the MPR alone method identiﬁed 29 (67.4%)
compared with the combination methods 19 (44.2%). The only
areas where the combination method outperformed the MPR
alone method were for comparing the top two cohorts in terms
of ARD-Speciﬁc comorbidities and for costs in the Emergency
Department. CONCLUSION: The MPR only method outper-
forms the MPR in combination with the existence of BEs at dif-
ferentiating patients with ARD.
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OBJECTIVE: Making process and technology changes in clini-
cal practice is often complex and costly. The interdependence of
processes, staff, technology and patients can bias static models.
Dynamic system simulations can identify problems, and solu-
tions, by imitating actual processes over time. Our objective was
to examine the efﬁciency possible with increased resources in 
an outpatient endoscopy unit using discrete event simulation.
METHODS: We designed a computer simulation model 
(AnylogicTM, AccessTM) of a three procedure room outpatient
endoscopy unit with eight shared preparation/recovery rooms.
Design involved documenting patient and staff ﬂow; determin-
ing process times via observation studies, chart reviews and staff
interviews; and validating output with actual performance data.
The model simulates 20 working days and generates mean daily
statistics. Outcome measures include patient throughput
(patients per day, PPD) and length of stay in minutes (LOS), cal-
culated as mean patient time from arrival to discharge. Scenar-
ios included doubling staff, adding combination responsibility
nurses or adding prep/recovery rooms to the baseline model.
RESULTS: At baseline, the unit averaged 17 PPD, 177 minute
LOS. Outcome statistics for scenarios are (PPD, LOS): doubled
staff (18, 164), one nurse (18, 168), two nurses (18, 166), one
room (19, 184), two rooms (20, 192). Two additional
prep/recovery rooms results in the largest throughput impact (+3
PPD), but increases LOS 15 minutes. The addition of one nurse
results in 98% of the throughput achieved with doubled staff (+1
PPD) and reduces LOS by nine minutes. CONCLUSIONS:
Increasing space capacity results in the largest throughput in this
unit suggesting a potential solution to patient backlogs over time.
However, adding one nurse both increases productivity and
reduces patient LOS. Diminishing marginal returns for increased
nursing units were observed. Further modeling may illuminate
strategies to optimize efﬁciency and proﬁt while also improving
measures of customer satisfaction (i.e., LOS).
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OBJECTIVE: The objective was to investigate whether a former
randomised study (the Nexium One study) reﬂects real-life in
